Skip to main content
Dermapharm Holding SE logo

Dermapharm Holding SE — Investor Relations & Filings

Ticker · DMP ISIN · DE000A2GS5D8 LEI · 5299009F0KNZINQQQK37 F Manufacturing
Open in API
Filings indexed 245 across all filing types
Latest filing 2024-12-30 Director's Dealing
Country DE Germany
Listing F DMP

About Dermapharm Holding SE

https://ir.dermapharm.de/index-EN.php

Dermapharm Holding SE is a manufacturer of branded pharmaceuticals and healthcare products, with a focus on the patent-free segment. The company operates an integrated business model that encompasses the entire value chain, including in-house research and development, production, and distribution. A dedicated pharmaceutical sales force manages the marketing and sales of its brand products. Dermapharm maintains a diversified portfolio concentrated on selected therapeutic areas, allowing it to establish strong market positions. The company operates several production, development, and distribution sites to support its operations and international expansion.

Recent filings

Filing Released Lang Actions
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and details a transaction (Acquisition) by a "person closely associated" (Themis Beteiligungs-Aktiengesellschaft, associated with Wilhelm Beier, a Member of the administrative or supervisory body) of the issuer's shares. This directly corresponds to the definition of Director's Dealing, which is classified as code DIRS.
2024-12-30 English
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the acquisition of shares by an individual associated with the administrative body (Wilhelm Beier) of Dermapharm Holding SE, including transaction dates, prices, and volumes. This directly corresponds to the definition of Director's Dealing.
2024-11-15 English
Q3 statement / Q3 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM STATEMENT Q3 2024' and contains comprehensive financial data, including a consolidated statement of financial position, statement of comprehensive income, and statement of cash flows for the nine-month period ending September 30, 2024. It provides detailed management analysis of revenue, earnings, and segment performance. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements, it is classified as an Interim/Quarterly Report. 9M 2024
2024-11-14 English
Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed tables reporting transactions (Acquisition) by a person discharging managerial responsibilities (Dr. Hans-Georg Feldmeier, Member of the managing body). This directly matches the definition for Director's Dealing (DIRS). The structure and content are typical of insider transaction disclosures.
2024-11-11 English
Report Publication Announcement 2024
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that the company 'hereby announces that the following financial reports shall be disclosed' and provides the date and location (URL) where the actual 'Quarterly/ Interim statement' will be available on November 14, 2024. Since the document itself is an announcement about the future release of a report, and not the report content, it fits the definition of a Report Publication Announcement (RPA). The document length (1848 chars) is also very short, supporting the RPA classification over the full Interim Report (IR).
2024-11-06 English
Dermapharm Holding SE: Christof Dreibholz, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the acquisition of shares by 'Christof Dreibholz', who is identified as a 'Member of the managing body'. This content directly matches the definition for Director's Dealing reports.
2024-11-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.